EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CRISPR‐Cas13d effectively targets SARS‐CoV‐2 variants, including Delta and Omicron, and inhibits viral infection

Zongzhi Liu, Xiang Gao, Chuanwen Kan, Lingyu Li, Yuan Zhang, Yibo Gao, Shengyuan Zhang, Liangji Zhou, Hui Zhao, Mingkun Li, Zheng Zhang, Yingli Sun iD

MedComm · 2023-02 · 4 (1)

DOI: 10.1002/mco2.208 ↗

Kurz gefasst

Fachartikel in der Zeitschrift MedComm, online erschienen am 31.01.2023. Verfasst von Zongzhi Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Central Laboratory National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital Chinese Academy of Medic…. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanming Project of Medicine in Shenzhen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The recent pandemic of variants of concern (VOC) of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) highlights the need for innovative anti‐SARS‐CoV‐2 approaches in addition to vaccines and antiviral therapeutics. Here, we demonstrate that a CRISPR‐Cas13‐based strategy against SARS‐CoV‐2 can effectively degrade viral RNA. First, we conducted a cytological infection experiment, screened CRISPR‐associated RNAs (crRNAs) targeting conserved regions of viruses, and used an in vitro system to validate functional crRNAs. Reprogrammed Cas13d effectors targeting NSP13, NSP14, and nucleocapsid transcripts achieved >99% silencing efficiency in human cells which are infected with coronavirus 2, including the emerging variants in the last 2 years, B.1, B.1.1.7 (Alpha), D614G B.1.351 (Beta), and B.1.617 (Delta). Furthermore, we conducted bioinformatics data analysis. We collected the sequence information of COVID‐19 and its variants from China, and phylogenetic analysis revealed that these crRNA oligos could target almost 100% of the SARS‐CoV family, including the emerging new variant, Omicron. The reprogrammed Cas13d exhibited high specificity, efficiency, and rapid deployment properties; therefore, it is promising for antiviral drug development. This system could possibly be used to protect against unexpected SARS‐CoV‐2 variants carrying multiple mutations.

Schlagwörter

Stichwörter der Autor:innen

CRISPR‐Cas systemRNAi therapySARS‐CoV‐2gene editing

Autor:innen und Institutionen

  • Central Laboratory National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Shenzhen China.
  • University of Chinese Academy of Sciences Beijing China.
  • CAS Key Laboratory of Genome Sciences and Information Beijing Institute of Genomics Chinese Academy of Sciences/China National Center for Bioinformation Beijing China.
  • Institute of Hepatology National Clinical Research Center for Infectious Disease School of Medicine Shenzhen Third People's Hospital The Second Affiliated Hospital Southern University of Science and Technology Shenzhen…
  • Beijing Institute of Genomics Chinese Academy of Sciences, China National Center for Bioinformation Beijing China.
  • Key Laboratory for Regenerative Medicine Ministry of Education School of Biomedical Sciences Faculty of Medicine The Chinese University of Hong Kong Hong Kong.

ORCID-Profile: Yingli Sun

Förderung

  • Sanming Project of Medicine in Shenzhen

Zitieren

APA

Liu, Z., Gao, X., Kan, C., Li, L., Zhang, Y., Gao, Y., Zhang, S., Zhou, L., Zhao, H., Li, M., Zhang, Z., & Sun, Y. (2023). CRISPR‐Cas13d effectively targets SARS‐CoV‐2 variants, including Delta and Omicron, and inhibits viral infection. MedComm, 4(1). https://doi.org/10.1002/mco2.208

Vancouver

Liu Z, Gao X, Kan C, Li L, Zhang Y, Gao Y, et al. CRISPR‐Cas13d effectively targets SARS‐CoV‐2 variants, including Delta and Omicron, and inhibits viral infection. MedComm. 2023;4(1). doi:10.1002/mco2.208

BibTeX
@article{Liu2023,
  author = {Liu, Zongzhi and Gao, Xiang and Kan, Chuanwen and Li, Lingyu and Zhang, Yuan and Gao, Yibo and Zhang, Shengyuan and Zhou, Liangji and Zhao, Hui and Li, Mingkun and Zhang, Zheng and Sun, Yingli},
  title = {CRISPR‐Cas13d effectively targets SARS‐CoV‐2 variants, including Delta and Omicron, and inhibits viral infection},
  journal = {MedComm},
  year = {2023},
  volume = {4},
  number = {1},
  doi = {10.1002/mco2.208}
}
Kostenlos starten →